{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:49:24Z","timestamp":1770446964569,"version":"3.49.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U19FD003800"],"award-info":[{"award-number":["U19FD003800"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R18FD005292"],"award-info":[{"award-number":["R18FD005292"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0156068","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T17:43:07Z","timestamp":1463593387000},"page":"e0156068","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-7665","authenticated-orcid":false,"given":"Karen","family":"Barnard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda C.","family":"Lakey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan C.","family":"Batch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asba","family":"Tasneem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"ref1","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","year":"2010"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"O Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00198-009-0835-z","article-title":"Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data","volume":"20","author":"H Cheng","year":"2009","journal-title":"Osteoporos Int"},{"key":"ref4","article-title":"The frequency of bone disease","year":"2004"},{"key":"ref5","unstructured":"Clinical Trials Transformation Initiative. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ctti-clinicaltrials.org\/home\" xlink:type=\"simple\">http:\/\/www.ctti-clinicaltrials.org\/home<\/ext-link>. Accessed 5 March 2014."},{"key":"ref6","unstructured":"ClinicalTrials.gov Protocol Registration System. PRS information. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/prsinfo.ClinicalTrials.gov\" xlink:type=\"simple\">http:\/\/prsinfo.ClinicalTrials.gov<\/ext-link>. Accessed 4 October 2012."},{"key":"ref7","unstructured":"U.S. Food and Drug Administration. Public Law 110\u201385. The Food and Drug Administration Amendments Act of 2007. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/FullTextofFDAAALaw\/default.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/FullTextofFDAAALaw\/default.htm<\/ext-link>. Accessed 31 May 2011."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e33677","DOI":"10.1371\/journal.pone.0033677","article-title":"The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty","volume":"7","author":"A Tasneem","year":"2012","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/joim.12366","article-title":"Osteoporosis: the emperor has no clothes","volume":"277","author":"TL J\u00e4rvinen","year":"2015","journal-title":"J Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jbmr.5650100517","article-title":"Prevalence of low femoral bone density in older U.S. women from NHANES III","volume":"10","author":"AC Looker","year":"1995","journal-title":"J Bone Miner Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1359\/jbmr.090706","article-title":"Prevalence and trends in low femur bone density among older US adults: NHANES 2005\u20132006 compared with NHANES III","volume":"25","author":"AC Looker","year":"2010","journal-title":"J Bone Miner Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"O Strom","year":"2011","journal-title":"Arch Osteoporos"},{"issue":"Suppl 2","key":"ref13","first-page":"S57","article-title":"The economic burden of fractures in the European Union in 2010","volume":"23","author":"J Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"R Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"73l","DOI":"10.1007\/s001980200100","article-title":"Survival and potential years of life lost after hip fracture in men and age-matched women","volume":"13","author":"A Trombetti","year":"2002","journal-title":"Osteoporos Int"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00198-004-1592-7","article-title":"Increasing hip fracture incidence in California Hispanics, 1983 to 2000","volume":"15","author":"DS Zingmond","year":"2004","journal-title":"Osteoporos Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"JE Rossouw","year":"2002","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"DM Black","year":"1996","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial","volume":"85","author":"DM Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"ST Harris","year":"1999","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"MR McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"DM Black","year":"2007","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"JS Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"RM Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"DM Black","year":"2003","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"SR Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"MR Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-010-1212-7","article-title":"Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study","volume":"22","author":"SR Majumdar","year":"2011","journal-title":"Osteoporos Int"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-004-1675-5","article-title":"Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review","volume":"15","author":"V Elliot-Gibson","year":"2004","journal-title":"Osteoporos Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2005.11.001","article-title":"Fragility fractures and the osteoporosis care gap: an international phenomenon","volume":"35","author":"L Giangregorio","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2318-9-28","article-title":"Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams","volume":"9","author":"DA Haaland","year":"2009","journal-title":"BMC Geriatr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"JA Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1001\/jama.2012.3424","article-title":"Characteristics of clinical trials registered in ClinicalTrials.gov, 2007\u20132010","volume":"307","author":"RM Califf","year":"2012","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s00125-013-2890-4","article-title":"Are current clinical trials in diabetes addressing important issues in diabetes care?","volume":"56","author":"W Lakey","year":"2013","journal-title":"Diabetologia"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0156068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:12:25Z","timestamp":1588986745000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0156068"}},"subtitle":[],"editor":[{"given":"Martijn","family":"van Griensven","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0156068","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}